Q-omics provides the consensus-scored GPR17 profile across patient tissues and cancer cell-line models. GPR17 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GPR17 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, GPR17 RNA expression shows 18,390 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight MESO, BLCA, and CCRCC as cancer lineages where GPR17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR17 survival associations across molecular data types. GPR17 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR17 RNA expression–survival associations across cancer types. High GPR17 expression shows unfavorable associations in MESO, but favorable associations in UVM, HNSC, LGG, PAAD and SARC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for GPR17 RNA expression.
This table summarizes GPR17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPR17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR17 shows lower tumor expression in BLCA, KICH, LUAD, KIRP, LUSC and COAD. The BLCA box plot shows higher GPR17 RNA expression in normal versus tumor tissue (log2 FC = −1.852, t-test p < 0.001).
This table shows molecular features associated with GPR17 in patient tissues and cancer cell lines. In patient samples, GPR17 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
